Latest News
Scancell in-licenses Vaccitech technology advancing Modi-2 towards the clinic
Scancell continue progress for Modi-2 by in-licencing Vaccitech technology.
Scancell enrols first patient in cancer trial expansion
Scancell said it has enrolled its first patient in the expansion phase of its ModiFY trial.
Scancell signs exclusive deal with cancer giant Genmab for anti-glycan antibody
Scancell Holdings, Calculus portfolio company, said it has signed a deal worth up to US$208m.
Scancell: As Covid mutates, the vaccine makers are adapting too
Scancell featured in the Guardian Focus on the exciting potential of T-cell immunity is spurring the sector on to create a new generation of jabs The speed at which scientists worked to develop the first Covid jabs was unprecedented. Just nine months after the UK went into lockdown, 90-year-old Margaret Keenan officially became the first person in … Continued
Could Scancell create the first ‘universal’ vaccine for Covid?
Approval granted for clinical trial in South Africa Vaccine targets the core of the virus, not just the spike protein eliciting a t-cell response which can destroy cells infected with any SARS CoV-2 variants and other SARS-CoV viruses that may emerge in the future. Scancell, the developer of novel immunotherapies for the treatment of cancer … Continued